Tenosynovial Giant Cell Tumor of the Retropharynx: A Case Report With Literature Review

Tenosynovial giant cell tumor (TSGCT) represents a family of benign tumors that arise from the synovial tissue of a joint, tendon sheath, or bursa. It usually involves the joints of the extremities and rarely occurs in the head and neck region. Here, we describe a case of a 32-year-old man with a submucosal mass bulging in the posterior pharyngeal wall since one month. The lesion was removed and diagnosed with localized type of TSGCT based on histopathological investigations and clinical presentation. It is very rare that TSGCT occurs in the retropharynx, which reminds clinicians to consider this entity as a possible diagnosis.

Download Full-text

ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)

Future Oncology ◽

10.2217/fon-2020-0307 ◽

2020 ◽

Vol 16 (25) ◽

pp. 1875-1878 ◽

Cited By ~ 1

Author(s):

William Tap

Keyword(s):

Side Effects ◽

Giant Cell Tumor ◽

Giant Cell ◽

Liver Function Tests ◽

Tendon Sheath ◽

Cell Tumor ◽

Hair Color ◽

Plain Language ◽

Clinical Trial Registration ◽

Tenosynovial Giant Cell Tumor

Pexidartinib is the first approved medication in the USA for people with tenosynovial giant cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at pexidartinib (brand name, Turalio™), a medication taken by mouth (orally) for people with TGCT (also known as giant cell tumor of the tendon sheath [GCTTS] and pigmented villonodular synovitis [PVNS]) who are not able to have surgery because of the location and/or the size of the tumor. The study showed that pexidartinib is effective in treating people with TGCT because it shrunk the size of their tumors and improved their symptoms and their ability to function. In general, people treated with pexidartinib had side effects that were mostly mild that went away after treatment with pexidartinib was stopped. The most common side effects were hair color changes and tiredness (fatigue). Pexidartinib was also associated with liver problems (or hepatotoxicity), which started within the first 2 months of treatment. Due to the risk of liver problems, which may be severe and potentially life threatening, the researchers closely monitored participants’ blood liver function tests before, during, and after participants in the study took pexidartinib. To read the full Plain Language Summary of this article, click on the View Article button above and download the PDF. Clinical Trial Registration: NCT02371369 ( ClinicalTrials.gov )

Download Full-text

A30: Giant Cell Tumor of the Tendon Sheath and/or Soft Tissue (Also Referred to as Nodular Tenosynovitis, Fibrous Xanthoma, Tenosynovial Giant Cell Tumor, and Benign Synovioma)

MRI of Bone and Soft Tissue Tumors and Tumorlike Lesions ◽

10.1055/b-0034-65704 ◽

2008 ◽

Keyword(s):

Soft Tissue ◽

Giant Cell Tumor ◽

Giant Cell ◽

Tendon Sheath ◽

Cell Tumor ◽

Tenosynovial Giant Cell Tumor

Download Full-text

Pediatric Tenosynovial Giant Cell Tumor of the Flexor Hallucis Longus Tendon Sheath

JBJS Case Connector ◽

10.2106/jbjs.cc.19.00519 ◽

2020 ◽

Vol 10 (2) ◽

pp. e0519-e0519

Author(s):

Richard D. Williams ◽

M. Wesley Honeycutt ◽

Elizabeth A. Manci ◽

Prasit Nimityongskul

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Tendon Sheath ◽

Cell Tumor ◽

Flexor Hallucis Longus ◽

Longus Tendon ◽

Tenosynovial Giant Cell Tumor

Download Full-text

Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence.

Oncology Reports ◽

10.3892/or.7.2.413 ◽

2000 ◽

Cited By ~ 4

Author(s):

R C Martin ◽

D L Osborne ◽

M J Edwards ◽

W Wrightson ◽

K M McMasters

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Surgical Therapy ◽

Tendon Sheath ◽

Pigmented Villonodular Synovitis ◽

Cell Tumor ◽

Villonodular Synovitis ◽

Tenosynovial Giant Cell Tumor ◽

Pigmented Villonodular

Download Full-text

Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)

Orthopaedics & Traumatology Surgery & Research ◽

10.1016/j.otsr.2016.11.002 ◽

2017 ◽

Vol 103 (1) ◽

pp. S91-S97 ◽

Cited By ~ 26

Author(s):

F. Gouin ◽

T. Noailles

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Tendon Sheath ◽

Pigmented Villonodular Synovitis ◽

Cell Tumor ◽

Villonodular Synovitis ◽

Tenosynovial Giant Cell Tumor ◽

Pigmented Villonodular

Download Full-text

Localized Tenosynovial Giant Cell Tumor of Tendon Sheath

Acta Cytologica ◽

10.1159/000328500 ◽

2000 ◽

Vol 44 (3) ◽

pp. 463-466 ◽

Cited By ~ 11

Author(s):

Monisha Choudhury ◽

Renu Jain ◽

Anita Nangia ◽

K.B. Logani

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Tendon Sheath ◽

Cell Tumor ◽

Tenosynovial Giant Cell Tumor

Download Full-text

Management of a Huge Tenosynovial Giant Cell Tumor of the Wrist

Archives of Hand and Microsurgery ◽

10.12790/ahm.21.0096 ◽

2021 ◽

Author(s):

Woo Jong Kim ◽

Sang Mi Lee ◽

Byungsung Kim ◽

Jae-Hwi Nho ◽

Jun Bum Kim ◽

...

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Rare Case ◽

Tendon Sheath ◽

Cell Tumor ◽

Benign Neoplasms ◽

Diffuse Type ◽

Giant Cell Tumors ◽

Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors (TGCTs) are typically benign neoplasms of the joint, bursa, and tendon sheath. Usually, TGCT presents as a small localized tumor on the hand and wrist. The diffuse-type TGCT is more aggressive and mainly affects large joints such as knees, hips, ankles, and elbows. Diffuse-type TGCT of small joints is rare. To our knowledge, this is a very rare case of a huge diffuse-type TGCT on the wrist. We report a huge TGCT, which grew gradually over 10 years.

Download Full-text

Tenosynovial giant cell tumor of the tendon sheat

Issues of Reconstructive and Plastic Surgery ◽

10.52581/1814-1471/77/11 ◽

2021 ◽

Vol 24 (2) ◽

pp. 100-107

Author(s):

M. A. Khodorkovskiy

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Kinase Inhibitors ◽

Benign Neoplasm ◽

Tendon Sheath ◽

Cell Tumor ◽

Adjuvant Radiation ◽

Tenosynovial Giant Cell Tumor ◽

Optical Magnification ◽

Plastic Reconstructive Surgery

The review article outlines modern aspects of the nomenclature, etiopathogenesis, diagnosis and treatment of tenosynovial giant cell tumor of the tendon sheath. This is the second most common benign neoplasm of the hand. Non-radical surgical treatment of this disease leads to a large number of recurrence. To avoid tumor recurrence, surgeon must to have the basics of plastic reconstructive surgery, use delicate instruments and optical magnification. In some cases, adjuvant radiation therapy and administration of tyrosine kinase inhibitors may be required.

Download Full-text

Atypical Tenosynovial Giant Cell Tumor of the Foot and Ankle: A Case Report

Journal of the American Podiatric Medical Association ◽

10.7547/18-038 ◽

2021 ◽

Vol 111 (3) ◽

Author(s):

Peter Awad

Keyword(s):

Soft Tissue ◽

Giant Cell Tumor ◽

Giant Cell ◽

Soft Tissue Tumor ◽

Imaging Modality ◽

Tendon Sheath ◽

Cell Tumor ◽

Tenosynovial Giant Cell Tumor ◽

Tissue Tumor ◽

Pathology Reports

Tenosynovial giant cell tumor, also known as giant cell tumor of the tendon sheath (GCT-TS), is a solitary, nodular, firm, benign, soft-tissue tumor that arises from the synovial lining of a tendon. The etiology is unknown. It is a rare soft-tissue tumor, with an overall incidence of one in 50,000 individuals, and usually affects people aged between 30 and 50 years. Magnetic resonance imaging tends to be the imaging modality of choice, used for surgical preparation. Widely accepted treatment involves local excision with or without radiotherapy. The author presents a case study involving a patient with an abnormally large, longstanding GCT-TS, diagnosed with clinical examination and imaging modalities, surgically excised, and further confirmed by pathology reports. Topic of discussion includes a review of GCT-TS.

Download Full-text